Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

A novel augmentation strategy for treating resistant major depression.

R C Shelton1, G D Tollefson, M Tohen

  • 1Department of Psychiatry, Vanderbilt University Medical Center, Nashville, TN 37212, USA. richard.shelton@mcmail.vanderbilt.edu

The American Journal of Psychiatry
|January 4, 2001
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Treatment of schizophrenic disorders: Algorithms for acute pharmacotherapy.

International journal of psychiatry in clinical practice·2014
Same author

Allosteric modulation of the muscarinic M4 receptor as an approach to treating schizophrenia.

Proceedings of the National Academy of Sciences of the United States of America·2008
Same author

Towards a muscarinic hypothesis of schizophrenia.

Molecular psychiatry·2006
Same author

The procholinergic effects of the atypical antipsychotic olanzapine are independent of muscarinic autoreceptor inhibition.

Molecular psychiatry·2006
Same author

Procholinergic and memory enhancing properties of the selective norepinephrine uptake inhibitor atomoxetine.

Molecular psychiatry·2005
Same author

Duloxetine (Cymbalta), a dual inhibitor of serotonin and norepinephrine reuptake.

Bioorganic & medicinal chemistry letters·2003

Adding olanzapine to fluoxetine significantly improved treatment-resistant depression more than either drug alone. This combination therapy offers a promising option for patients with difficult-to-treat depression.

Area of Science:

  • Psychiatry
  • Clinical Pharmacology

Background:

  • Treatment-resistant depression (TRD) poses a significant public health challenge.
  • Standard treatments like drug switching or augmentation yield limited success in TRD patients.

Purpose of the Study:

  • To investigate the efficacy of augmenting fluoxetine with olanzapine for TRD.
  • To compare the combination therapy against monotherapy with either drug.

Main Methods:

  • An 8-week double-blind study involved 28 patients with recurrent, nonbipolar TRD.
  • Participants were randomized into three groups: olanzapine/placebo, fluoxetine/placebo, or olanzapine/fluoxetine.

Main Results:

  • Fluoxetine monotherapy showed minimal antidepressant effects.

Related Experiment Videos

  • Olanzapine monotherapy provided modest benefits.
  • The combination of olanzapine and fluoxetine demonstrated significantly greater improvement in depression severity after one week compared to monotherapy.

    • Conclusions:

    • Olanzapine combined with fluoxetine is more effective for treating resistant depression than either medication alone.
    • The combination therapy showed no significant differences in extrapyramidal symptoms or adverse drug interactions compared to monotherapy.